Biotron Ltd has released a press release.
Presentation at BIO 2019
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Earlier from Biotron
- Presentation of BIT225-009 hiv-1 phase 2 data
- Response to ASX aware letter
- Biotron Secures $4.7 Million Underwriting Agreement
- $1.07 million R&D Tax Incentive Received
- Significant Immunological Outcomes in BIT225 HIV-1 Trial
Later from Biotron
- Appointment of International Advisory Board for BIT225
- Presentation to Investors
- Biotron Secures $5.1 Million Underwriting Agreement
- Biotron to Test its Compounds Against Coronavirus
- BIT225 restores immune function in hiv-1 infections
Follow Biotron into a list and get an email when it puts out news.
Follow Biotron